Evodia rutaecarpa for Health & Longevity

Evidence Review created on 10/13/2026 using AI4L + evidence-mcp / Wonder 1.0

Also known as: Euodia rutaecarpa, Tetradium ruticarpum, Wu Zhu Yu, Evodiae Fructus, Evodia Fruit

Motivation

Evodia rutaecarpa is a plant whose dried, nearly ripe fruit has a long history of use in East Asian herbal practice. The fruit contains naturally occurring compounds, mainly evodiamine and rutaecarpine, that influence how the body senses warmth and pain, how blood vessels relax, and how cells handle inflammation and growth. Those actions explain why the fruit has attracted interest well beyond its traditional setting, including for weight, circulation, and healthy ageing.

Traditional use centred on pain, digestive upset, headache, and cold-related discomfort, usually as part of multi-herb preparations rather than on its own. Modern laboratory work has since examined the isolated compounds in cells and animals, while human testing remains very limited. That gap between extensive laboratory study and sparse human study is the central tension in the evidence, and it shapes how much weight any claimed benefit or harm can carry.

This review examines what is known about Evodia rutaecarpa for health and longevity: what the fruit and its compounds do in the body, which benefits and risks have actually been observed in people, which rest only on laboratory or animal findings, and what practical and safety questions remain unresolved.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews that discuss Evodia rutaecarpa or its main compounds in substantial depth.

A broad narrative review covering traditional uses, chemistry, and laboratory activities of the plant group that includes this fruit, with a clear statement that human trials are still needed.

Focuses on rutaecarpine and blood-vessel, heart, and lipid effects in laboratory and animal work, including the warmth-sensing and vessel-relaxing pathways involved.

Reviews the main alkaloids (plant nitrogen-containing compounds) in relation to digestive conditions, summarising cell and animal findings and the limits of current evidence.

An early overview of evodiamine and cancer-cell growth in laboratory studies, useful for understanding why oncology interest developed despite the absence of human cancer trials.

No relevant content from the prioritised experts listed in the search statement was found, so none is included. Fewer than five items are listed because additional high-level overviews either duplicate these reviews or are systematic reviews, which belong in the Systematic Reviews section.

Grokipedia

Tetradium ruticarpum

Covers the plant under its accepted botanical name, including traditional use as Wu Zhu Yu, chemistry, and reported pharmacological activities, providing a general reference entry point.

Examine

Evodia rutaecarpa

States that no human studies of the berries exist, summarises traditional decoction amounts, and notes poor oral availability (how much reaches the blood after swallowing) of isolated compounds.

ConsumerLab

No ConsumerLab article on Evodia rutaecarpa exists as of 13/10/2026. The site search returned only an unrelated warning letter, with no dedicated review or product testing for this intervention.

Systematic Reviews

This section lists systematic reviews and meta-analyses (studies that systematically gather and, where possible, statistically combine prior studies) identified on PubMed.

No systematic review of a longevity, mortality, or human safety outcome was found, so the principal-risk side of the trade-off is unrepresented in this section.

Combines mouse tumour experiments only; it does not test cancer outcomes in people and therefore does not establish a human benefit.

Systematically reviews cell and animal digestive-disease work and notes that toxicity findings remain contested across experiments.

Combines animal studies of evodiamine given with other cancer treatments; human relevance remains untested in controlled trials.

Reviews evodiamine pharmacology, toxicity, and pharmacokinetics across laboratory and animal studies; human clinical confirmation remains absent.

Mechanism of Action

Evodiamine and rutaecarpine are the best-studied alkaloids in the dried fruit. Evodiamine activates the transient receptor potential vanilloid 1 channel (TRPV1; a warmth- and pain-sensing channel also activated by capsaicin, the hot compound in chilli), which can alter pain signalling, heat sensation, and energy expenditure (energy burned by the body). In fat-cell and mouse studies it also reduced fat-cell formation through extracellular signal-regulated kinase signalling (ERK; a cell-growth signalling chain) and reduced insulin signalling through protein kinase B (Akt; a protein that relays insulin signals), an effect independent of uncoupling protein 1 (UCP1; a mitochondrial protein that releases energy as heat) Wang et al.. Rutaecarpine activates the same warmth-sensing channel on sensory nerves, increasing calcitonin gene-related peptide (CGRP; a small protein that relaxes blood vessels) synthesis and release, which relaxed blood vessels and lowered blood pressure in hypertensive rats Deng et al.. Both compounds also affect inflammatory signalling, including nuclear factor kappa B (NF-κB; a protein complex that switches on inflammatory genes) Zhou et al.. Human pharmacokinetic data are lacking: in human liver preparations, evodiamine was broken down mainly by cytochrome P450 3A4, 2C9, and 1A2 enzymes (CYP3A4, CYP2C9, CYP1A2; liver enzymes that break down many medicines) Sun et al., with poor water solubility and low oral availability reported in reviews Sun et al.. Half-life, tissue distribution, and selectivity in people have not been established. Competing explanations for the anti-obesity signal — heat production versus reduced fat-cell formation — both remain preclinical.

Historical Context & Evolution

The dried fruit, known in Chinese practice as Wu Zhu Yu, has been used for centuries in China, Japan, and Korea for headache, abdominal pain, vomiting, diarrhoea, mouth sores, and menstrual pain, most often combined with other herbs rather than used alone Zhao et al.. Formulae such as Wu Zhu Yu decoction and Zuo Jin Wan illustrate that traditional pattern: the fruit was one component whose warming and pain-relieving reputation was balanced by other ingredients. Interest in health optimisation arose much later, after laboratory isolation of evodiamine and rutaecarpine showed effects on fat cells, blood vessels, inflammation, and cancer-cell growth in the 1990s and 2000s. That work reframed a traditional digestive and pain remedy as a possible metabolic and cardiovascular compound, and supplement marketing followed the animal fat-loss findings. Scientific opinion has since become more cautious rather than settled: comprehensive reviews through 2024 repeatedly note promising cell and animal pharmacology, contested toxicity findings, poor oral availability of isolated alkaloids, and the absence of well-designed randomized controlled trials (RCTs; studies in which participants are randomly assigned to treatment or control) in people Zhao et al.. What changed was not proof of human benefit, but clearer recognition of the gap between preclinical activity and clinical evidence, including reports linking fruit preparations to liver injury that require explanation rather than dismissal.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human randomized trial tested body composition and resting metabolic rate (RMR; energy burned at rest), and all other claimed benefits rest on animal or cell studies without a human clinical endpoint.

Medium 🟩 🟩

No benefit reaches Medium: no human benefit has been shown in a single controlled trial with a between-group advantage for Evodia rutaecarpa, and consistent observational human data with a comparison group are absent.

Low 🟩

Weight and Body Composition ⚠️ Conflicted

Mice report less fat formation with evodiamine Wang et al.. A 125-woman trial tested evodia during dieting Kim et al.. Body mass index (BMI; weight relative to height) fell in groups, with no evodia advantage. Species and dieting context may explain the difference. The net reading is no weight benefit.

Magnitude: Not quantified in available studies. Body mass index fell within the evodia and placebo groups during dieting, not compared between groups as an evodia-specific outcome figure in the trial summary.

Speculative 🟨

Cardiovascular and Blood-Pressure Effects in Animals

Rutaecarpine lowered blood pressure in hypertensive rats through vessel-relaxing peptide release Deng et al.. Human blood-pressure outcomes have not been tested.

Blood-Lipid and Platelet Effects in Animals

Rutaecarpine showed lipid-lowering and platelet-related actions in laboratory and animal work reviewed by Tian et al.. Controlled human lipid or platelet outcomes have not been tested.

Anticancer Activity in Cells and Animals

Meta-analyses (statistical combinations of prior studies) combine only mouse tumour experiments showing smaller tumours with evodiamine Yin et al.. No human cancer prevention or treatment outcome has been studied.

Anti-Inflammatory Effects

Reviews describe anti-inflammatory actions of the main alkaloids in cells and animals Chen et al.. Controlled human evidence for inflammation outcomes is absent.

Pain Effects

Reviews describe pain-related actions of the main alkaloids in cells and animals Chen et al.. Controlled human evidence for pain relief is absent.

Digestive Effects

Reviews describe digestive actions of the main alkaloids in cells and animals Chen et al.. Controlled human evidence for digestion outcomes is absent.

Brain Effects

Reviews describe brain-related actions of the main alkaloids in cells and animals Chen et al.. Controlled human evidence for cognition or brain ageing is absent.

Antimicrobial Effects in Laboratory Studies

Laboratory work in the Tetradium review reports antibacterial activity in cells and animals Zhao et al.. Controlled human infection outcomes have not been tested.

Benefit-Modifying Factors

  • Genetic differences in liver enzymes: Variation in the liver enzymes that break down evodiamine could change exposure, but no human pharmacogenetic (gene-related drug response) study has tested dose or benefit by genotype.
  • Baseline body weight and diet: The only human trial combined evodia with a low-calorie diet in women with obesity; any signal cannot be separated from dieting or baseline weight.
  • Baseline biomarker levels: No human study has tested whether baseline inflammation, blood-lipid, or blood-sugar measures modify benefit; available human data report weight outcomes during dieting only.
  • Sex: Human data come solely from premenopausal women, so benefit modification by sex is unknown rather than established.
  • Pre-existing conditions: Traditional digestive and pain uses concern symptomatic conditions, whereas longevity use in healthy adults has no direct human evidence base.
  • Age: No trial enrolled older adults, so whether age changes benefit, exposure, or tolerability remains unstudied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human adverse outcome has been shown in controlled trials from more than one independent research group, and controlled human safety data are limited to one short trial.

Medium 🟥 🟥

No risk reaches Medium: no human adverse outcome has been shown in a single controlled trial or in consistent observational data with a comparison group; the main signals come from case reports, reviews, and animal work.

Low 🟥

Liver Injury ⚠️ Conflicted

Reviews link Evodiae Fructus to liver injury via reactive metabolites (chemically reactive breakdown products) Yan et al.. An eight-week randomized trial found no adverse serum-test findings Kim et al.. Short duration and uncontrolled case reporting may explain the difference. The net reading is an unquantified signal unconfirmed in controlled testing.

Magnitude: Not quantified in available studies. No controlled study has measured liver-injury rates, so no comparison-group rate exists.

Gastrointestinal Irritation

Reviews associate the warming fruit with digestive upset Zhao et al.. Human frequency data are uncontrolled reports and short trial questionnaires without a clear excess over placebo.

Magnitude: Not quantified in available studies. No controlled study reports a comparison-group rate for these symptoms.

Warmth and Flushing Symptoms

Reviews associate the warming fruit with flushing and heat sensation Zhao et al.. Human frequency data are uncontrolled reports and short trial questionnaires without a clear excess over placebo.

Magnitude: Not quantified in available studies. No controlled study reports a comparison-group rate for these symptoms.

Speculative 🟨

Heart Toxicity

Reviews of evodiamine report heart-toxicity signals in preclinical work alongside liver toxicity Sun et al.. No controlled human heart outcome, rhythm, or blood-pressure harm has been established.

Harm From Isolated High-Dose Alkaloids

Animal and cell work suggests dose-dependent toxicity from isolated evodiamine and related fruit compounds, including rutaevin activation in liver preparations Liu et al.. Whether supplement doses reproduce this in people is unknown.

Risk-Modifying Factors

  • Genetic differences in liver enzymes: Variants affecting the enzymes that activate or clear fruit compounds could alter formation of reactive breakdown products; human genotype-specific risk is untested.
  • Baseline liver health: Pre-existing liver disease or raised liver enzymes (proteins released when liver cells are injured) could plausibly increase susceptibility to liver injury.
  • Sex: Short-term human safety data come from premenopausal women only, leaving sex-based risk differences unknown.
  • Pre-existing conditions: Low blood pressure, heart disease, pregnancy, and digestive disorders could change tolerability, but controlled data in these groups are absent.
  • Age: Older adults, who often use more medicines and have reduced liver reserve, were not studied in the human trial.

Key Interactions & Contraindications

  • Medicines cleared by CYP1A2 (a liver enzyme that breaks down drugs such as caffeine and theophylline): Caution (theoretical) — rutaecarpine induced this enzyme in rats and changed caffeine handling Estari et al.; altered medicine levels are possible. Medicine review and monitoring apply.
  • Medicines cleared by CYP2C9 or CYP2D6 (liver enzymes; warfarin, metoprolol): Caution (theoretical) — evodiamine inhibited these enzymes in rats Zhang et al.; higher medicine exposure is possible. Medicine review and monitoring apply.
  • Medicines cleared by CYP3A4 (a liver enzyme; simvastatin, midazolam): Caution (theoretical) — a fruit compound inactivated this enzyme in human liver preparations Liu et al.; human confirmation is lacking. Medicine review and monitoring apply.
  • Blood-pressure-lowering medicines (amlodipine, losartan) and supplements: Caution (theoretical) — vessel-relaxing effects in animals could add to blood-pressure lowering; no human interaction study exists. Blood-pressure monitoring applies.
  • Caffeine and stimulant supplements: Caution (theoretical) — altered caffeine clearance in rats and warmth-channel activity could change stimulant response and sleep. Medicine and supplement review applies.
  • Over-the-counter pain and cold medicines (ibuprofen, dextromethorphan): Caution (theoretical) — many are cleared by the same liver enzymes; no human interaction data exist. Medicine review applies.

Populations who should avoid Evodia rutaecarpa:

  • Pregnancy and breastfeeding, due to absent human safety data and traditional uterine (womb) activity concerns
  • People with liver disease or unexplained raised liver enzymes
  • Children and adolescents, due to absent human safety data
  • People scheduled for surgery, due to theoretical blood-pressure and medicine-clearance effects

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Liver-test awareness: Baseline liver enzymes, repeated at one month and then every three to six months during use, address the liver-injury signal; a sourced stop threshold has not been established.
  • Avoid isolated high-dose alkaloids: Concentrated evodiamine products carry the dose-dependent liver and heart toxicity signals seen in laboratory work; whole-fruit preparations differ in what reaches the blood.
  • Medicine review before use: Checking prescription, over-the-counter, and supplement lists addresses theoretical liver-enzyme interactions described above.
  • Blood-pressure and heart-rate checks: Monitoring addresses the vessel-relaxing and preclinical heart signals when blood-pressure medicines are also used.
  • Stop for concerning symptoms: Jaundice (yellowing of skin or eyes), dark urine, severe nausea, palpitations (felt racing heartbeat), or fainting signal possible liver or heart harm and warrant stopping and seeking medical assessment.

Therapeutic Protocol

Other parameters without a citation (e.g., timing, cycling, titration steps) reflect common practice.

  • No established longevity protocol: No clinical guideline, product label, or leading-practitioner protocol establishes dose, duration, or target outcome for health and longevity use.
  • Human trial regimen: The only randomized trial used capsules providing evodiamine 6.75 mg and rutaecarpine 0.66 mg alongside a low-calorie diet for eight weeks Kim et al..
  • Traditional decoction amount: Examine summarises traditional use as 3–9 g of berries made into a decoction (a boiled water extract), divided into two or three servings daily Examine.
  • Time of day: No human study establishes best time of day; warmth and stimulant-like effects are the practical consideration reported for related compounds.
  • Half-life and split dosing: Human half-life (time for blood levels to fall by half) is not established, so single versus split dosing has no evidence base in people.
  • Genetics, sex, and age: No pharmacogenetic, sex-based, or age-based dosing adjustment is supported by human data; trial data are limited to premenopausal women.
  • Baseline factors: Baseline liver-enzyme, blood-pressure, and body-weight measures are recorded for safety and trial context, but no human study has tested whether baseline biomarker levels change response.
  • Pre-existing conditions: Liver disease, low blood pressure, heart disease, pregnancy, and digestive disorders may change response or tolerability; no condition-specific dosing is supported by human data.

Discontinuation & Cycling

  • Duration of use: Traditional use was for defined symptom episodes, and the human trial lasted eight weeks; lifelong longevity use has no supporting safety data.
  • Withdrawal effects: No withdrawal syndrome has been reported for the fruit or its alkaloids in human studies.
  • Tapering: No tapering protocol has been studied; abrupt stopping has not been reported to cause rebound effects in the available literature.
  • Cycling: No cycling schedule has been tested for maintaining effect or reducing liver or heart risk.

Sourcing and Quality

  • Species and plant part: Authentic material is the dried, nearly ripe fruit of the named species; substitution with related Tetradium species changes alkaloid content.
  • Alkaloid standardisation: Products vary in evodiamine and rutaecarpine content, and reviews identify these alkaloids as quality markers for medicinal material Zhao et al..
  • Third-party testing: Independent testing for identity, alkaloid amount, heavy metals, pesticides, and microbial contamination addresses the main quality gaps in imported botanical material.
  • Preparation form: Whole-fruit decoction, ethanol (alcohol) extract, and isolated alkaloid capsules differ in what reaches the blood, so they are not interchangeable.
  • Reputable supply: No specific brand or compounding pharmacy can be endorsed from the evidence reviewed; sellers providing batch test results offer stronger quality evidence.

Practical Considerations

  • Time to effect: No human time-to-effect has been established; the only trial assessed outcomes after four and eight weeks of dieting.
  • Common pitfalls: Treating animal fat-loss findings as human proof, and treating isolated evodiamine capsules as equivalent to whole fruit, are the central errors in marketing.
  • Regulatory status: The fruit is sold as a herbal or dietary supplement; the U.S. Food and Drug Administration (FDA; the U.S. medicines and food regulator) regulates supplements under different rules than drug products FDA.
  • Cost and access: Concentrated alkaloid products and imported fruit vary widely in price and availability, with no established benefit to justify premium pricing.

Interaction with Foundational Habits

  • Sleep: Indirect — altered caffeine clearance in rats could change caffeine persistence and sleep, but no human sleep study of the fruit exists; evening stimulant combinations are the practical concern.
  • Nutrition: Direct — traditional use and the only trial pair the fruit with food or dieting; fat-cell effects in animals were diet-dependent, and taking it with a calorie-controlled diet confounds any weight reading.
  • Exercise: None established — no study has tested training performance, muscle gain, or workout timing with the fruit or its alkaloids in people. No workout-timing adjustment is supported.
  • Stress management: Indirect — warmth, pain, and digestive effects could influence perceived stress, but no human study has measured stress hormones (chemical messengers such as cortisol) or stress outcomes. Recording perceived stress alongside warmth and digestive symptoms is the practical option.

Monitoring Protocol & Defining Success

Baseline testing addresses liver safety, blood pressure, heart rate, weight, and medicine burden before any use, because those are the domains where a signal or a theoretical interaction exists. Ongoing monitoring repeats liver tests and vital signs early, then less often if stable, alongside weight and symptom tracking. No sourced optimal functional range exists for this intervention, so conventional laboratory reference ranges are used and change from personal baseline is tracked where no target exists. Qualitative markers are recorded in parallel because benefit claims concern warmth, pain, digestion, and energy rather than a validated laboratory outcome.

Ongoing monitoring cadence in the available trial context was assessment at four and eight weeks; beyond that, a cadence of liver tests and blood-pressure checks at one month, then every three to six months reflects common practice unless cited.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase 7–56 units per litre (standard reference range) Safety check — stops or changes use A liver enzyme released when liver cells are injured; fasting not required; compare with personal baseline
Aspartate aminotransferase 10–40 units per litre (standard reference range) Safety check — stops or changes use A liver enzyme also found in muscle; interpret with alanine aminotransferase; exercise can raise it transiently
Total bilirubin (a breakdown product cleared by the liver) 0.1–1.2 mg/dL (standard reference range) Safety check — stops or changes use Raised values with symptoms warrant prompt assessment
Blood pressure No established target — track change from personal baseline instead Safety and expected-change marker Measure seated after rest, same time of day; no sourced optimal range is given for this intervention
Resting heart rate 60–100 beats per minute (standard reference range) Safety check — changes use Track with blood pressure and palpitation symptoms
Body weight No established target — track change from personal baseline instead Expected-change marker Weigh under consistent conditions; diet changes confound readings
  • Warmth and flushing: Frequency and intensity of heat sensation or flushing after use
  • Digestive symptoms: Nausea, stomach pain, vomiting, or diarrhoea frequency
  • Pain and headache: Headache or pain days per week, recorded consistently
  • Energy and sleep: Perceived energy and sleep quality, especially with caffeine use

Emerging Research

  • Herb-partitioned moxibustion (heat applied at body points) trial NCT04606680: No ongoing evodia-specific trial was found. This 108-person obesity trial (phase not applicable; status UNKNOWN, completion 2021, no results posted; primary endpoint clinical effectiveness at week 4) tested a multi-herb preparation containing Evodia rutaecarpa, not the fruit alone; neither result would establish an evodia-specific effect.
  • Liver-safety clarification: Work on reactive breakdown products of fruit compounds could strengthen or weaken the liver concern Yan et al., 2023; a controlled human safety study would settle frequency.
  • Digestive-disease translation: The 2024 systematic review found positive animal digestive findings with contested toxicity Zhou et al.; human trials would test whether that signal survives translation.
  • Cancer combination claims: Animal meta-analysis favoured evodiamine combinations over evodiamine alone Zheng et al., 2025; no human cancer trial is registered, so clinical relevance remains open.

Conclusion

Evodia rutaecarpa is a traditional East Asian fruit whose main compounds affect warmth and pain sensing, blood-vessel relaxation, inflammation, and cell growth in laboratory systems. That breadth explains interest for weight, circulation, digestion, pain, and healthy ageing, yet the human record remains exceptionally thin. A single short trial in women following a low-calorie diet found weight change across all groups without a clear advantage for this fruit, and it was not designed to test ageing, lifespan, or long-term safety. Every other claimed benefit rests on animal or cell findings, which can identify possibilities but cannot show that people live longer, stay healthier, or avoid disease.

The risk picture is similarly incomplete and cannot be treated as settled in either direction. Reports linking fruit preparations to liver injury, laboratory findings of liver and heart toxicity at higher exposures, and plausible interference with the breakdown of many common medicines all argue for caution, while short-term human testing has not shown a clear harm signal. Product form matters throughout, since whole fruit, extracts, and isolated compounds reach the body very differently and are often marketed as if identical. Overall, the evidence base is best characterised as extensive early laboratory exploration with minimal human confirmation, substantial uncertainty about both benefit and harm, and no demonstrated relevance to longevity outcomes in people.

Top - Benefits - Risks - Protocol